News summary

SPLASH: a benchtop platform for accessible, ultrasensitive quantification of plasma biomarkers in Alzheimer’s disease

Source: Nature - Biotechnology • Published: 07 Oct 2026, 00:00

Summarized by Masters of Longevity from Nature - Biotechnology.

A new benchtop proximity ligation assay, SPLASH, enables ultrasensitive plasma protein quantification for Alzheimer’s biomarkers using standard qPCR equipment.

SPLASH: a benchtop platform for accessible, ultrasensitive quantification of plasma biomarkers in Alzheimer’s disease
Key Takeaways
  • SPLASH achieved sub-pg/mL limits of detection for five AD biomarkers, ranging from 0.0005 to 0.119 pg/mL.
  • Plasma pTau-217 measured by SPLASH discriminated amyloid-positive from amyloid-negative individuals with AUC = 0.839.
  • SPLASH is compatible with dried plasma spot samples enabling decentralized collection without cold-chain storage.
Read the full article at Nature - Biotechnology ↗

Continue exploring

Recommended MoL Picks

MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.